stockrow
Saturday 7 November 2026
Export IGC’s income statement to Excel — free account
IGC Pharma, Inc.
IGC Pharma, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $1.3 million, down 5.50% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- 0.00%
- Free cash flow
- −45.3%
- Total debt
- +558.3%
Quarter to September 2026, against a year earlier
0.19
0.00
0.00%
Follow IGC
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
26.85 | 24.60 | 21.89 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(20.86) | (20.07) | (20.87) | — | |
P/B ratio |
4.55 | 4.42 | 4.17 | — | |
Price to Tangible BV |
38.85 | 43.34 | 29.92 | — | |
EV/Sales |
27.26 | 25.27 | 22.47 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(5.61) | (5.21) | (5.55) | — | |
EV/FCF |
(5.27) | (4.89) | (5.56) | — | |
Quick Ratio |
0.16 | 0.13 | 0.09 | 0.44 | |
Current Ratio |
0.42 | 0.39 | 0.40 | 0.83 | |
Net Debt/EBITDA |
0.00 | (0.27) | (0.28) | 0.00 | |
Debt/Assets |
8.93% | 11.39% | 9.98% | 3.20% | |
Debt/Equity |
0.13 | 0.18 | 0.15 | 0.04 | |
Asset Turnover |
0.11 | 0.13 | 0.13 | 0.00 | |
Operating CF/Net income |
0.69 | 0.46 | 0.51 | — | |
Capex/Depreciation |
0.00 | (7.55) | (0.02) | — | |
Research and Development Expense of Revenue |
308.84% | 524.53% | 401.26% | — | |
Selling, General and Administrative Expense of Revenue |
298.48% | 544.15% | 391.48% | — | |
Intangible Assets out of Total Assets |
0.59 | 0.58 | 0.57 | 0.53 | |
Share Based Compensation of Revenue |
118.90% | 281.89% | 318.30% | — | |
Graham Net Nets |
(0.06) | (0.08) | (0.08) | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(33.33%) | (33.33%) | (28.85%) | — | |
Free Cash Flow Yield |
(19.27%) | (20.99%) | (18.47%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | — | |
Operating CF per Share |
(0.01) | (0.01) | (0.01) | — | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(0.01) | (0.02) | (0.01) | — | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.06 | 0.06 | 0.06 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.06 | 0.06 | 0.06 | 0.00 | |
Free Cash Flow |
(1.42) | (1.77) | (1.22) | — | |
Working Capital |
(1.79) | (1.95) | (1.73) | (0.37) | |
Capital Expenditures |
— | (0.42) | 0.00 | — | |
Net Current Asset Value |
(1.92) | (2.10) | (1.92) | (0.50) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.00 | 1.60 | 0.00 | — | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.05 | 0.07 | 0.04 | 0.03 | |
Average Payables |
1.14 | 1.28 | 1.07 | 0.92 | |
Average Inventory |
0.65 | 0.99 | 1.00 | 1.04 | |
Average Assets |
9.74 | 8.72 | 8.97 | 9.40 | |
Average Common Equity |
7.30 | 6.11 | 6.23 | 6.84 |
Columns are period end dates · fundamentals updated 6 Nov 2026